

Myasthenia Gravis Treatment Market By Drug class (Monoclonal antibodies, Intravenous immunoglobulin, Others), By Age group (Below 55 years, Above 55 years), By Distribution channel (Hospital pharmacies, Drug store and retail pharmacies, Online providers): Global Opportunity Analysis and Industry Forecast, 2023-2032

Market Report | 2023-04-01 | 263 pages | Allied Market Research

AVAILABLE LICENSES:

- Cloud Access License \$3110.40
- Business User License \$5157.00
- Enterprise License \$8640.00

Report description:

The global myasthenia gravis treatment market was valued at \$1.7 billion in 2022, and is projected to reach \$3.1 billion by 2032, growing at a CAGR of 6.5% from 2023 to 2032.

Myasthenia gravis (MG) is an autoimmune disease caused by antibodies that attack and damage the receptors at the neuromuscular junction, leading to muscle weakness and fatigue. In addition, the antibodies target the acetylcholine receptor (AChR), which is a protein located on the postsynaptic membrane of the neuromuscular junction. Moreover, in some cases, the antibodies may target other proteins related to the acetylcholine receptor (AChR), such as muscle-specific kinase (MuSK). This leads to impaired communication between the nerve and muscle, which results in muscle weakness and fatigue. □

The most common symptoms of myasthenia gravis include muscle weakness, particularly in the eyes, face, throat & limbs, difficulty speaking, swallowing, or breathing, drooping eyelids, double vision, and fatigue that worsens with activity. Currently, there are several drugs available for the treatment of myasthenia gravis, such as acetylcholinesterase inhibitors, corticosteroids, immunosuppressants, intravenous immunoglobulin (IVIg), and monoclonal antibodies. □

The major factor driving the growth of myasthenia gravis treatment market are increase in number of patients suffering from myasthenia gravis, advancements in diagnosis of autoimmune disorders, and rise in availability of treatment options for myasthenia gravis. The rise in prevalence of myasthenia gravis worldwide is one of the primary drivers for the growth of the myasthenia gravis treatment market. For instance, according to the Myasthenia Gravis Foundation of America, approximately 14 to 20 out of 100,000 people in the U.S. are affected by myasthenia gravis, and the disease is more common in women than men.

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Moreover, the incidence of myasthenia gravis has increased globally, which is expected to drive the demand for effective treatments for the disease.□

Furthermore, increase in the diagnosis of myasthenia gravis is expected to fuel the market growth. Myasthenia gravis is a rare and often misdiagnosed autoimmune disorder that affects the neuromuscular junction, leading to muscle weakness and fatigue. The disease can be challenging to diagnose, as symptoms may be subtle or vary greatly from person to person. However, advancements in diagnostic techniques have led to more accurate and timely diagnosis of myasthenia gravis, which drives the market growth. The surge in the diagnosis of myasthenia gravis has increased the demand for effective treatments and fosters market growth. As more cases of myasthenia gravis are identified and diagnosed earlier, there is a greater need for effective treatments to manage the disease and prevent complications. This has led to increased investment in R&D □of new and more effective treatments for myasthenia gravis. □

Furthermore, the increase in diagnosis has led to greater awareness of the disease among patients and healthcare professionals. In addition, increase in number of drugs in clinical stages of development, focused on treatment of myasthenia gravis is anticipated to boost the growth of market. As the number of people affected by myasthenia gravis continues to increase, the demand for effective treatments rises, resulting in need for innovative therapies. This demand drives the pharmaceutical companies and research institutions to invest in the development of new treatments for the disease, with clinical trials serving as a critical tool for testing their safety and efficacy. Thus, upsurge in number of clinical trials focused on myasthenia gravis is expected to drive the growth of the myasthenia gravis treatment market by providing new and improved treatments for patients suffering from myasthenia gravis disease.□

The myasthenia gravis treatment market is segmented into drug class, age group, distribution channel, and region. On the basis of drug class, the market is categorized into cholinesterase inhibitors, immunosuppressants, monoclonal antibodies, intravenous immunoglobulin (IVIg), and others. On the basis of age group, the market is bifurcated into below 50 years and above 50 years. On the basis of distribution channel, the market is segregated into hospital pharmacies, drug stores & retail pharmacies, and online providers. Region wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).□

Major key players that operate in the global myasthenia gravis treatment market are F. Hoffmann-La Roche Ltd., AstraZeneca, Novartis AG, Zydus Lifesciences Limited, Bausch Health Companies, Inc., CSL Limited, Grifols, S.A., Octapharma AG, Astellas Pharma Inc., and Kedrion, SpA. The key players have adopted strategies such as acquisition, agreement, strategic alliance, product approval, and expansion to expand their product portfolio.□

Key Benefits For Stakeholders

- This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the myasthenia gravis treatment market analysis from 2022 to 2032 to identify the prevailing myasthenia gravis treatment market opportunities.
- The market research is offered along with information related to key drivers, restraints, and opportunities.
- Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
- In-depth analysis of the myasthenia gravis treatment market segmentation assists to determine the prevailing market opportunities.
- Major countries in each region are mapped according to their revenue contribution to the global market.
- Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
- The report includes the analysis of the regional as well as global myasthenia gravis treatment market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments

By Drug class

- Intravenous immunoglobulin
- Others
- Monoclonal antibodies

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

By Age group

- Below 55 years
- Above 55 years

By Distribution channel

- Hospital pharmacies
- Drug store and retail pharmacies
- Online providers

By Region

- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- Japan
- China
- India
- Rest of Asia-Pacific
- LAMEA
- Latin America
- Middle East And Africa
- Key Market Players
- Astellas Pharma Inc.
- AstraZeneca
- Bausch Health Companies, Inc.
- CSL Limited
- F. Hoffmann-La Roche Ltd.
- Grifols, S.A.
- Kedrion, SpA
- Novartis AG
- Octapharma AG
- Zydus Lifesciences Limited

Table of Contents:

CHAPTER 1: INTRODUCTION

- 1.1. Report description
- 1.2. Key market segments
- 1.3. Key benefits to the stakeholders
- 1.4. Research Methodology
 - 1.4.1. Primary research
 - 1.4.2. Secondary research

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

2.1. CXO Perspective

CHAPTER 3: MARKET OVERVIEW

3.1. Market definition and scope

3.2. Key findings

3.2.1. Top impacting factors

3.2.2. Top investment pockets

3.3. Porter's five forces analysis

3.3.1. Bargaining power of suppliers

3.3.2. Bargaining power of buyers

3.3.3. Threat of substitutes

3.3.4. Threat of new entrants

3.3.5. Intensity of rivalry

3.4. Market dynamics

3.4.1. Drivers

3.4.1.1. Rise in demand of effective treatments for myasthenia gravis

3.4.1.2. Surge in prevalence of myasthenia gravis

3.4.1.3. Advancements in R&D of novel drugs

3.4.2. Restraints

3.4.2.1. Side effects and high cost associated with treatments for myasthenia gravis

3.4.3. Opportunities

3.4.3.1. Growth opportunities in emerging markets

3.5. COVID-19 Impact Analysis on the market

CHAPTER 4: MYASTHENIA GRAVIS TREATMENT MARKET, BY DRUG CLASS

4.1. Overview

4.1.1. Market size and forecast

4.2. Monoclonal antibodies

4.2.1. Key market trends, growth factors and opportunities

4.2.2. Market size and forecast, by region

4.2.3. Market share analysis by country

4.3. Intravenous immunoglobulin

4.3.1. Key market trends, growth factors and opportunities

4.3.2. Market size and forecast, by region

4.3.3. Market share analysis by country

4.4. Others

4.4.1. Key market trends, growth factors and opportunities

4.4.2. Market size and forecast, by region

4.4.3. Market share analysis by country

CHAPTER 5: MYASTHENIA GRAVIS TREATMENT MARKET, BY AGE GROUP

5.1. Overview

5.1.1. Market size and forecast

5.2. Below 55 years

5.2.1. Key market trends, growth factors and opportunities

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 5.2.2. Market size and forecast, by region
- 5.2.3. Market share analysis by country
- 5.3. Above 55 years
 - 5.3.1. Key market trends, growth factors and opportunities
 - 5.3.2. Market size and forecast, by region
 - 5.3.3. Market share analysis by country
- CHAPTER 6: MYASTHENIA GRAVIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL
 - 6.1. Overview
 - 6.1.1. Market size and forecast
 - 6.2. Hospital pharmacies
 - 6.2.1. Key market trends, growth factors and opportunities
 - 6.2.2. Market size and forecast, by region
 - 6.2.3. Market share analysis by country
 - 6.3. Drug store and retail pharmacies
 - 6.3.1. Key market trends, growth factors and opportunities
 - 6.3.2. Market size and forecast, by region
 - 6.3.3. Market share analysis by country
 - 6.4. Online providers
 - 6.4.1. Key market trends, growth factors and opportunities
 - 6.4.2. Market size and forecast, by region
 - 6.4.3. Market share analysis by country
- CHAPTER 7: MYASTHENIA GRAVIS TREATMENT MARKET, BY REGION
 - 7.1. Overview
 - 7.1.1. Market size and forecast By Region
 - 7.2. North America
 - 7.2.1. Key trends and opportunities
 - 7.2.2. Market size and forecast, by Drug class
 - 7.2.3. Market size and forecast, by Age group
 - 7.2.4. Market size and forecast, by Distribution channel
 - 7.2.5. Market size and forecast, by country
 - 7.2.5.1. U.S.
 - 7.2.5.1.1. Key market trends, growth factors and opportunities
 - 7.2.5.1.2. Market size and forecast, by Drug class
 - 7.2.5.1.3. Market size and forecast, by Age group
 - 7.2.5.1.4. Market size and forecast, by Distribution channel
 - 7.2.5.2. Canada
 - 7.2.5.2.1. Key market trends, growth factors and opportunities
 - 7.2.5.2.2. Market size and forecast, by Drug class
 - 7.2.5.2.3. Market size and forecast, by Age group
 - 7.2.5.2.4. Market size and forecast, by Distribution channel
 - 7.2.5.3. Mexico
 - 7.2.5.3.1. Key market trends, growth factors and opportunities
 - 7.2.5.3.2. Market size and forecast, by Drug class
 - 7.2.5.3.3. Market size and forecast, by Age group
 - 7.2.5.3.4. Market size and forecast, by Distribution channel
 - 7.3. Europe
 - 7.3.1. Key trends and opportunities

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 7.3.2. Market size and forecast, by Drug class
- 7.3.3. Market size and forecast, by Age group
- 7.3.4. Market size and forecast, by Distribution channel
- 7.3.5. Market size and forecast, by country
 - 7.3.5.1. Germany
 - 7.3.5.1.1. Key market trends, growth factors and opportunities
 - 7.3.5.1.2. Market size and forecast, by Drug class
 - 7.3.5.1.3. Market size and forecast, by Age group
 - 7.3.5.1.4. Market size and forecast, by Distribution channel
 - 7.3.5.2. France
 - 7.3.5.2.1. Key market trends, growth factors and opportunities
 - 7.3.5.2.2. Market size and forecast, by Drug class
 - 7.3.5.2.3. Market size and forecast, by Age group
 - 7.3.5.2.4. Market size and forecast, by Distribution channel
 - 7.3.5.3. UK
 - 7.3.5.3.1. Key market trends, growth factors and opportunities
 - 7.3.5.3.2. Market size and forecast, by Drug class
 - 7.3.5.3.3. Market size and forecast, by Age group
 - 7.3.5.3.4. Market size and forecast, by Distribution channel
 - 7.3.5.4. Italy
 - 7.3.5.4.1. Key market trends, growth factors and opportunities
 - 7.3.5.4.2. Market size and forecast, by Drug class
 - 7.3.5.4.3. Market size and forecast, by Age group
 - 7.3.5.4.4. Market size and forecast, by Distribution channel
 - 7.3.5.5. Spain
 - 7.3.5.5.1. Key market trends, growth factors and opportunities
 - 7.3.5.5.2. Market size and forecast, by Drug class
 - 7.3.5.5.3. Market size and forecast, by Age group
 - 7.3.5.5.4. Market size and forecast, by Distribution channel
 - 7.3.5.6. Rest of Europe
 - 7.3.5.6.1. Key market trends, growth factors and opportunities
 - 7.3.5.6.2. Market size and forecast, by Drug class
 - 7.3.5.6.3. Market size and forecast, by Age group
 - 7.3.5.6.4. Market size and forecast, by Distribution channel
- 7.4. Asia-Pacific
 - 7.4.1. Key trends and opportunities
 - 7.4.2. Market size and forecast, by Drug class
 - 7.4.3. Market size and forecast, by Age group
 - 7.4.4. Market size and forecast, by Distribution channel
 - 7.4.5. Market size and forecast, by country
 - 7.4.5.1. Japan
 - 7.4.5.1.1. Key market trends, growth factors and opportunities
 - 7.4.5.1.2. Market size and forecast, by Drug class
 - 7.4.5.1.3. Market size and forecast, by Age group
 - 7.4.5.1.4. Market size and forecast, by Distribution channel
 - 7.4.5.2. China
 - 7.4.5.2.1. Key market trends, growth factors and opportunities

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 7.4.5.2.2. Market size and forecast, by Drug class
- 7.4.5.2.3. Market size and forecast, by Age group
- 7.4.5.2.4. Market size and forecast, by Distribution channel
- 7.4.5.3. India
 - 7.4.5.3.1. Key market trends, growth factors and opportunities
 - 7.4.5.3.2. Market size and forecast, by Drug class
 - 7.4.5.3.3. Market size and forecast, by Age group
 - 7.4.5.3.4. Market size and forecast, by Distribution channel
- 7.4.5.4. Rest of Asia-Pacific
 - 7.4.5.4.1. Key market trends, growth factors and opportunities
 - 7.4.5.4.2. Market size and forecast, by Drug class
 - 7.4.5.4.3. Market size and forecast, by Age group
 - 7.4.5.4.4. Market size and forecast, by Distribution channel
- 7.5. LAMEA
 - 7.5.1. Key trends and opportunities
 - 7.5.2. Market size and forecast, by Drug class
 - 7.5.3. Market size and forecast, by Age group
 - 7.5.4. Market size and forecast, by Distribution channel
 - 7.5.5. Market size and forecast, by country
 - 7.5.5.1. Latin America
 - 7.5.5.1.1. Key market trends, growth factors and opportunities
 - 7.5.5.1.2. Market size and forecast, by Drug class
 - 7.5.5.1.3. Market size and forecast, by Age group
 - 7.5.5.1.4. Market size and forecast, by Distribution channel
 - 7.5.5.2. Middle East And Africa
 - 7.5.5.2.1. Key market trends, growth factors and opportunities
 - 7.5.5.2.2. Market size and forecast, by Drug class
 - 7.5.5.2.3. Market size and forecast, by Age group
 - 7.5.5.2.4. Market size and forecast, by Distribution channel

CHAPTER 8: COMPETITIVE LANDSCAPE

- 8.1. Introduction
- 8.2. Top winning strategies
- 8.3. Product Mapping of Top 10 Player
- 8.4. Competitive Dashboard
- 8.5. Competitive Heatmap
- 8.6. Top player positioning, 2022

CHAPTER 9: COMPANY PROFILES

- 9.1. Zydus Lifesciences Limited
 - 9.1.1. Company overview
 - 9.1.2. Key Executives
 - 9.1.3. Company snapshot
 - 9.1.4. Operating business segments
 - 9.1.5. Product portfolio
 - 9.1.6. Business performance
- 9.2. Novartis AG
 - 9.2.1. Company overview
 - 9.2.2. Key Executives

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 9.2.3. Company snapshot
- 9.2.4. Operating business segments
- 9.2.5. Product portfolio
- 9.2.6. Business performance
- 9.3. AstraZeneca
 - 9.3.1. Company overview
 - 9.3.2. Key Executives
 - 9.3.3. Company snapshot
 - 9.3.4. Operating business segments
 - 9.3.5. Product portfolio
 - 9.3.6. Business performance
 - 9.3.7. Key strategic moves and developments
- 9.4. Bausch Health Companies, Inc.
 - 9.4.1. Company overview
 - 9.4.2. Key Executives
 - 9.4.3. Company snapshot
 - 9.4.4. Operating business segments
 - 9.4.5. Product portfolio
 - 9.4.6. Business performance
- 9.5. CSL Limited
 - 9.5.1. Company overview
 - 9.5.2. Key Executives
 - 9.5.3. Company snapshot
 - 9.5.4. Operating business segments
 - 9.5.5. Product portfolio
 - 9.5.6. Business performance
 - 9.5.7. Key strategic moves and developments
- 9.6. Grifols, S.A.
 - 9.6.1. Company overview
 - 9.6.2. Key Executives
 - 9.6.3. Company snapshot
 - 9.6.4. Operating business segments
 - 9.6.5. Product portfolio
 - 9.6.6. Business performance
 - 9.6.7. Key strategic moves and developments
- 9.7. Octapharma AG
 - 9.7.1. Company overview
 - 9.7.2. Key Executives
 - 9.7.3. Company snapshot
 - 9.7.4. Operating business segments
 - 9.7.5. Product portfolio
 - 9.7.6. Business performance
- 9.8. Astellas Pharma Inc.
 - 9.8.1. Company overview
 - 9.8.2. Key Executives
 - 9.8.3. Company snapshot
 - 9.8.4. Operating business segments

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 9.8.5. Product portfolio
- 9.8.6. Business performance
- 9.9. Kedrion, SpA
 - 9.9.1. Company overview
 - 9.9.2. Key Executives
 - 9.9.3. Company snapshot
 - 9.9.4. Operating business segments
 - 9.9.5. Product portfolio
 - 9.9.6. Business performance
 - 9.9.7. Key strategic moves and developments
- 9.10. F. Hoffmann-La Roche Ltd.
 - 9.10.1. Company overview
 - 9.10.2. Key Executives
 - 9.10.3. Company snapshot
 - 9.10.4. Operating business segments
 - 9.10.5. Product portfolio
 - 9.10.6. Business performance

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Myasthenia Gravis Treatment Market By Drug class (Monoclonal antibodies, Intravenous immunoglobulin, Others), By Age group (Below 55 years, Above 55 years), By Distribution channel (Hospital pharmacies, Drug store and retail pharmacies, Online providers): Global Opportunity Analysis and Industry Forecast, 2023-2032

Market Report | 2023-04-01 | 263 pages | Allied Market Research

To place an Order with Scotts International:

- Print this form
- Complete the relevant blank fields and sign
- Send as a scanned email to support@scotts-international.com

ORDER FORM:

Select license	License	Price
	Cloud Access License	\$3110.40
	Business User License	\$5157.00
	Enterprise License	\$8640.00
		VAT
		Total

*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

** VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Address*	<input type="text"/>	City*	<input type="text"/>
Zip Code*	<input type="text"/>	Country*	<input type="text"/>
		Date	<input type="text" value="2025-05-10"/>
		Signature	<input type="text"/>